Clonazolam (also known as clonitrazolam) is a drug of the triazolobenzodiazepine (TBZD) class, which are benzodiazepines (BZDs) fused with a triazole ring. It has had very little research done about its effects and metabolism, and has been sold online as a designer drug.
The synthesis of clonazolam was first reported in 1971 and the drug was described as the most active compound in the series tested.
Clonazolam is reported to be highly potent and concerns have been raised that it and flubromazolam in particular may pose comparatively higher risk than other designer benzodiazepines due to their ability to produce strong sedation and amnesia at as little as 0.5 mg
clonazolam has been classified as a Class C drug by the May 2017 amendment to The Misuse of Drugs Act 1971 along with several other designer benzodiazepine drugs.
It is a Schedule I medicine in Virginia, Louisiana, North Carolina and Oregon and is not FDA approved for human consumption. Virginia State Law has declared all of the following medications are now schedule I: clonazolam, etizolam, flualprazolam, flubromazolam, and flubromazepam. Minnesota declared clonazolam a Schedule I drug in August 2020.